Massive Real-World study tracks targeted therapy success in early lung cancer

NCT ID NCT07593248

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen May 18, 2026 · Last updated May 20, 2026 · Updated 1 time

Summary

This study will follow about 2,000 people in China who have a specific type of lung cancer (EGFR-mutated) and have had surgery. After surgery, they take a targeted pill (EGFR-TKI) to try to prevent the cancer from coming back. Researchers will track how long patients live and how long they stay cancer-free over 5 years, using real-world data from hospitals.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.